Custom Search

Monday, February 28, 2011

FDA approval angiotensin II receptor blocker ARB antihypertensive drug Edarbi Tablets azilsartan medoxomil

A new angiotensin II receptor blocker (ARB) drug for treating high hypertension blood pressure in adult is approved by U.S. F DA
Edarbi tablets (azilsartan medoxomil) are now approved by US FDA for treating high blood pressure and hypertension in adults. Edarbi tablet which contains azilsartan medoxomil active pharmaceutical ingredient it is a angiotensin II receptor blocker (ARB) drug which reduces the pressor action of angiotensin II by directly blocking angiotensin II receptor. Drug Edarbi is available in doses of 80 mg and 40 mg of azilsartan medoxomil.
Angiotensin II receptor blockers act by following mechanism reduced vassopressor action and by reducing sodium retention. The first angiotensin II receptor blocker approved was Losartan

Information About Renin and Angiotensin System:
Angiotensin II is a peptide molecule which is responsible for peripheral vasoconstriction which result in to increase in vascular tone and thus increases blood pressure as the resistance for blood flow increases, and for increase in blood volume as at the same time, angiotensin also stimulates the release of a hormone called aldosteron which is produced in adrenal cortex, aldosteron reduces sodium and chloride excretion.

Angiotensin II is produced in our body from its precursor angiotensinogen it is produced in liver.
Angiotensinogen is first converted to angiotensinI by action of hormon called as renin and angiotensinI is then converted to angitensin II by action of enzyme called as angiotensin converting enzyme (ACE).

Renin is a enzyme which also act as a hormone it is secreted by kidney as a result of feed back mechanism.
1. Whenever there less sodium and chloride available in blood.
2. Whenever blood volume drops down , 3. Whenever the arterial blood pressure is decreased

Angiotensin converting enzyme (ACE) which also responsible for degradation of vasodialator bradykinin.
Most of the drugs which are required to reduce blood pressure act on renin and angiotensin syetm , they act either by inhibiting enzyme renin or angiotensin converting enzyme (ACE) or by directly blocking angiotensin II receptors. Other category of drug which is called as diuretics which act by increasing the excretion of sodium and chloride act by increased rate of urination and water excretion which result in lowering of blood volume.

High blood pressure or hypertension is most critical factor which increases risk of stroke and heart attack , congestive cardiac failure, kidney failure ,and bulging of arteries known as aneurysm which may result in to hemorrhage a life threatening condition.

It was found in clinical trials that Edarbi was effective in lowering 24 hour blood pressure as compared to other drugs earlier approved by antihypertensive drugs by FDA Benicar (olmesartan) and Diovan (valsartan).
Drug Edarbi should not be proscribed or taken by a pregnant women as it may harm developing fetus in second or third trimester. A boxed warning is given on the lable of the drug regarding the use in pregnancy as well. The drug should be discontinued by women if she get pregnant.

Drug Edarbi is manufactured Pharmaceutical Company Takeda Pharmaceutical North America of Deerfield, Ill.

You may also like
What is an artificial pacemaker device

Propranolol its use in hypertention

Process validation in Pharmaceutical

Pharma sales jobs Find best pharmaceutical company sales Job

No comments:

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org